JANX Quote, Financials, Valuation and Earnings

Arvinas has a net margin of -6391.57% compared to Janux Therapeutics's net margin of 43.91%. Janux Therapeutics's return on equity of -11.37% beat Arvinas's return on equity of -7.72%.

Janux Therapeutics has a consensus price target of $84.12, signalling upside risk potential of 220.95%. On the other hand Arvinas has an analysts' consensus of $19.36 which suggests that it could grow by 157.12%. Given that Janux Therapeutics has higher upside potential than Arvinas, analysts believe Janux Therapeutics is more attractive than Arvinas.

Janux Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Arvinas has a beta of 2.192, suggesting its more volatile than the S&P 500 by 119.176%.

Janux Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arvinas offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Janux Therapeutics pays -- of its earnings as a dividend. Arvinas pays out -- of its earnings as a dividend.

Janux Therapeutics quarterly revenues are $439K, which are smaller than Arvinas quarterly revenues of $188.8M. Janux Therapeutics's net income of -$23.5M is lower than Arvinas's net income of $82.9M. Notably, Janux Therapeutics's price-to-earnings ratio is -- while Arvinas's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics is 114.35x versus 1.27x for Arvinas. Usually stocks with elevated PS ratios are considered overvalued.

Blueprint Medicines has a net margin of -6391.57% compared to Janux Therapeutics's net margin of 0.33%. Janux Therapeutics's return on equity of -11.37% beat Blueprint Medicines's return on equity of -49.13%.

Janux Therapeutics has a consensus price target of $84.12, signalling upside risk potential of 220.95%. On the other hand Blueprint Medicines has an analysts' consensus of $126.87 which suggests that it could fall by -0.77%. Given that Janux Therapeutics has higher upside potential than Blueprint Medicines, analysts believe Janux Therapeutics is more attractive than Blueprint Medicines.

Janux Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Blueprint Medicines has a beta of 0.841, suggesting its less volatile than the S&P 500 by 15.895%.

Janux Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Blueprint Medicines offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Janux Therapeutics pays -- of its earnings as a dividend. Blueprint Medicines pays out -- of its earnings as a dividend.

Janux Therapeutics quarterly revenues are $439K, which are smaller than Blueprint Medicines quarterly revenues of $149.4M. Janux Therapeutics's net income of -$23.5M is lower than Blueprint Medicines's net income of $496K. Notably, Janux Therapeutics's price-to-earnings ratio is -- while Blueprint Medicines's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics is 114.35x versus 14.58x for Blueprint Medicines. Usually stocks with elevated PS ratios are considered overvalued.

Fortress Biotech has a net margin of -6391.57% compared to Janux Therapeutics's net margin of -80.55%. Janux Therapeutics's return on equity of -11.37% beat Fortress Biotech's return on equity of --.

Janux Therapeutics has a consensus price target of $84.12, signalling upside risk potential of 220.95%. On the other hand Fortress Biotech has an analysts' consensus of $10.00 which suggests that it could grow by 400%. Given that Fortress Biotech has higher upside potential than Janux Therapeutics, analysts believe Fortress Biotech is more attractive than Janux Therapeutics.

Janux Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Fortress Biotech has a beta of 1.764, suggesting its more volatile than the S&P 500 by 76.434%.

Janux Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fortress Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Janux Therapeutics pays -- of its earnings as a dividend. Fortress Biotech pays out -10.24% of its earnings as a dividend.

Janux Therapeutics quarterly revenues are $439K, which are smaller than Fortress Biotech quarterly revenues of $13.1M. Janux Therapeutics's net income of -$23.5M is lower than Fortress Biotech's net income of -$10.6M. Notably, Janux Therapeutics's price-to-earnings ratio is -- while Fortress Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics is 114.35x versus 0.78x for Fortress Biotech. Usually stocks with elevated PS ratios are considered overvalued.

Innoviva has a net margin of -6391.57% compared to Janux Therapeutics's net margin of -52.56%. Janux Therapeutics's return on equity of -11.37% beat Innoviva's return on equity of -8.85%.

Janux Therapeutics has a consensus price target of $84.12, signalling upside risk potential of 220.95%. On the other hand Innoviva has an analysts' consensus of $55.00 which suggests that it could grow by 154.87%. Given that Janux Therapeutics has higher upside potential than Innoviva, analysts believe Janux Therapeutics is more attractive than Innoviva.

Janux Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Innoviva has a beta of 0.371, suggesting its less volatile than the S&P 500 by 62.922%.

Janux Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Innoviva offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Janux Therapeutics pays -- of its earnings as a dividend. Innoviva pays out -- of its earnings as a dividend.

Janux Therapeutics quarterly revenues are $439K, which are smaller than Innoviva quarterly revenues of $88.6M. Janux Therapeutics's net income of -$23.5M is higher than Innoviva's net income of -$46.6M. Notably, Janux Therapeutics's price-to-earnings ratio is -- while Innoviva's PE ratio is 98.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Janux Therapeutics is 114.35x versus 4.32x for Innoviva. Usually stocks with elevated PS ratios are considered overvalued.